Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Damaged renal tissue" refers to kidney tissue that has undergone pathological injury due to conditions such as acute kidney injury, chronic kidney disease, ischemia, toxin exposure, or immune-mediated damage. The process involves complex interactions between epithelial, stromal, and immune cells, resulting in inflammation, cell death, tubular atrophy, fibrosis, and loss of functional nephrons. A wide variety of biomarkers (e.g., KIM-1, NGAL, periostin) indicate the presence of ongoing injury or fibrotic transformation but do not constitute a singular therapeutic molecule or receptor[2][3][6][1]. This term describes a tissue state, not a discrete molecule, protein, receptor, or other canonical drug target category, and should not be classified as a molecular therapeutic target[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Damaged renal tissue.